Aptose Biosciences

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Aptose Biosciences sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).

7 total trials 1 currently recruiting 3 completed early-phase tilt upper quartile by trial count

Aptose Biosciences: 7 sponsored US clinical trials, 1 recruiting.

Aptose Biosciences sponsors 7 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 3 completed. 0 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Relapsed Adult AML, with 1 trials.

Upper-quartile sponsor footprint

Aptose Biosciences sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Open and recent trials

7 total, page 1 of 1

RECRUITING Phase 1

Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT03850574
TERMINATED Phase 1

A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS

NCT04477291
TERMINATED Phase 1

A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas

NCT03893682
TERMINATED Phase 1

A Study of APTO-253 in Patients With Relapsed or Refractory AML or MDS

NCT02267863
COMPLETED Phase 1

A Study of LOR-253 HCl in Patients With Advanced or Metastatic Solid Tumours

NCT01281592
COMPLETED Phase 2

Combination of GTI-2040 and Cytarabine in the Treatment of Refractory and Relapsed Acute Myeloid Leukemia (AML)

NCT00565058
COMPLETED Phase 1

Combination of Capecitabine and GTI-2040 in the Treatment of Renal Cell Carcinoma

NCT00056173

Phase Distribution

PhaseTrial count
Phase 1 6
Phase 2 1

Therapeutic Areas

Relapsed Adult AML 1
Refractory AML 1
Myelodysplastic Syndrome With Excess Blasts-2 1
Leukemia, Myeloid, Acute 1
Chronic Myelomonocytic Leukemia 1

What is open in the Aptose Biosciences pipeline

1 recruiting of 7 indexed (14% open); 3 completed (43%).

Phase mix: 0 late (III/IV) vs 7 early (I/II) (early-phase heavy).

Top condition: Relapsed Adult AML (1 trial), 4 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Aptose Biosciences: open-pipeline peers nationwide

Peers matched on 7 registered trials and 14% open enrollment, not the therapeutic-area sidebar.

Aptose Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 01020304050 0%10%20%30%40% Total trials Recruiting share Aptose Biosciences3M4Life Research89bioAbbott Diagnostics DivisionAcademic and Community Cancer Research UnitedAdaptive BiotechnologiesAgelessRxAlaska Blind Child Discovery
Aptose Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Aptose Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 7 trials (± recruiting share)

Sponsors near 14% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Aptose Biosciences page

7 registered trials is a research-attention snapshot, not an endorsement of Aptose Biosciences or any single study.

  • 1 of Aptose Biosciences's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Relapsed Adult AML is the condition Aptose Biosciences studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Relapsed Adult AML trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Aptose Biosciences pipeline card: 7 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.